Ovid Therapeutics publishes corporate presentation on OV329 and OV4071 pipeline updates

Reuters03-18

Ovid <a href="https://laohu8.com/S/LENZ">Therapeutics</a> publishes corporate presentation on OV329 and OV4071 pipeline updates

Ovid said it received regulatory approval to initiate a Phase 1 study of OV4071, an oral potassium-chloride cotransporter 2 direct activator. The company also reported that a 7 mg dose of OV329, a GABA-aminotransferase inhibitor, showed no treatment-related serious adverse events or adverse events in healthy volunteers. Ovid said it plans to initiate a Phase 2 randomized controlled trial of OV329 in treatment-resistant focal onset seizures in Q2 2026 and expects Phase 2 topline results in mid-2027. The company said it entered into a PIPE financing expected to generate gross proceeds of USD 60 million and noted potential additional proceeds of up to USD 53 million from Series A warrants if exercised in full. Ovid said that, with completion of the PIPE and assuming full exercise of the warrants, it expects cash runway into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620255226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620255226","market":"us","top_or_hot":-1,"title":"Ovid Therapeutics publishes corporate presentation on OV329 and OV4071 pipeline updates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> publishes corporate presentation on OV329 and OV4071 pipeline updates\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ovid said it received regulatory approval to initiate a Phase 1 study of OV4071, an oral potassium-chloride cotransporter 2 direct activator. The company also reported that a 7 mg dose of OV329, a GABA-aminotransferase inhibitor, showed no treatment-related serious adverse events or adverse events in healthy volunteers. Ovid said it plans to initiate a Phase 2 randomized controlled trial of OV329 in treatment-resistant focal onset seizures in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 and expects Phase 2 topline results in mid-2027. The company said it entered into a PIPE financing expected to generate gross proceeds of USD 60 million and noted potential additional proceeds of up to USD 53 million from Series A warrants if exercised in full. Ovid said that, with completion of the PIPE and assuming full exercise of the warrants, it expects cash runway into 2029.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ovid Therapeutics publishes corporate presentation on OV329 and OV4071 pipeline updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOvid Therapeutics publishes corporate presentation on OV329 and OV4071 pipeline updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 20:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> publishes corporate presentation on OV329 and OV4071 pipeline updates\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ovid said it received regulatory approval to initiate a Phase 1 study of OV4071, an oral potassium-chloride cotransporter 2 direct activator. The company also reported that a 7 mg dose of OV329, a GABA-aminotransferase inhibitor, showed no treatment-related serious adverse events or adverse events in healthy volunteers. Ovid said it plans to initiate a Phase 2 randomized controlled trial of OV329 in treatment-resistant focal onset seizures in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 and expects Phase 2 topline results in mid-2027. The company said it entered into a PIPE financing expected to generate gross proceeds of USD 60 million and noted potential additional proceeds of up to USD 53 million from Series A warrants if exercised in full. Ovid said that, with completion of the PIPE and assuming full exercise of the warrants, it expects cash runway into 2029.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OVID","symbol_name":"Ovid Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLb8jlQk:1","article_id":"2620255226","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620255226","pubTimestamp":1773837892,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ovid said it received regulatory approval to initiate a Phase 1 study of OV4071, an oral potassium-chloride cotransporter 2 direct activator. The company also reported that a 7 mg dose of OV329, a GABA-aminotransferase inhibitor, showed no treatment-related serious adverse events or adverse events in healthy volunteers. Ovid said it plans to initiate a Phase 2 randomized controlled trial of OV329 in treatment-resistant focal onset seizures in Q2 2026 and expects Phase 2 topline results in mid-2027. The company said it entered into a PIPE financing expected to generate gross proceeds of USD 60 million and noted potential additional proceeds of up to USD 53 million from Series A warrants if exercised in full. Ovid said that, with completion of the PIPE and assuming full exercise of the warrants, it expects cash runway into 2029.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OVID":"Ovid Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Ovid Therapeutics发布有关OV329和OV4071管道更新的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OVID":0.9},"content_text":"Ovid Therapeutics publishes corporate presentation on OV329 and OV4071 pipeline updates\n    \n\n        Ovid said it received regulatory approval to initiate a Phase 1 study of OV4071, an oral potassium-chloride cotransporter 2 direct activator. The company also reported that a 7 mg dose of OV329, a GABA-aminotransferase inhibitor, showed no treatment-related serious adverse events or adverse events in healthy volunteers. Ovid said it plans to initiate a Phase 2 randomized controlled trial of OV329 in treatment-resistant focal onset seizures in Q2 2026 and expects Phase 2 topline results in mid-2027. The company said it entered into a PIPE financing expected to generate gross proceeds of USD 60 million and noted potential additional proceeds of up to USD 53 million from Series A warrants if exercised in full. Ovid said that, with completion of the PIPE and assuming full exercise of the warrants, it expects cash runway into 2029.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620255226","isCrawlerRequest":true}